This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Eric A. F. Simoes, MD, DCH; Baby Padmini, MSc; Mark C. Steinhoff, MD; Malati Jadhav, MD, DCH; T. Jacob John, FRCP(E), PhD

Am J Dis Child. 1985;139(10):977-980.

Abstract
• The conventional formulation of injectable poliovirus vaccine (inactivated) contains 20, 2, and 4 D-antigen units of types 1, 2, and 3 polioviruses. Primary immunization requires three doses given at intervals of at least four weeks. A new formulation with 40, 8, and 32 D-antigen units of the three poliovirus types has been prepared to reduce primary immunization to two doses. We evaluated the immunogenic efficacy of this new formulation supplied to us as a liquid vaccine containing diphtheria-pertussis-tetanus vaccines and inactivated poliovirus vaccine. Two doses were administered four weeks apart to 100 infants and eight weeks apart to 114 infants. Antibody titers were determined against the three types of polioviruses before and after immunization. The effects of age, presence of maternal antibody, and interval between doses on the frequency and titers of antibody response were assessed. Irrespective of age or interval between doses, the seroconversion rates to types 1 and 3 antigens were 90% to 100%. To type 2 antigen the rate was below 84% in the 6- to 7-week-old infants, 88% to 95% in 8- to 12-week-old infants, and 90% to 100% in 13- to 45-week-old infants. The seroconversion rates and geometric mean titers of antibody were lower in those infants with maternal antibody than in those without maternal antibody at the time of receiving the first dose. The best results were in infants 8 weeks of age or older, in whom the two doses were given eight weeks apart. We recommend this schedule.

(AJDC 1985;139:977-980)

Author Affiliations
From the Department of Child Health and the Indian Council of Medical Research Centre of Advanced Research in Virology, Christian Medical College and Hospital, Vellore, India.

Footnotes
Reprint requests to Indian Council of Medical Research Centre of Advanced Research in Virology, CMC Hospital, Vellore, Tamilnadu 632004, India (Dr John).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba
The Cuba IPV Study Collaborative Group
NEJM 2007;356:1536-1544.
ABSTRACT | FULL TEXT  

Polio vaccine: is it time for a change? • Commentary
Finn et al.
Arch. Dis. Child. 1998;78:571-574.
FULL TEXT  

Pediatric Immunizations: A Review
O'Brien
Journal of Pharmacy Practice 1989;2:21-27.
ABSTRACT  

Paralytic Poliomyelitis--Senegal, 1986-1987: Update on the N-IPV Efficacy Study
JAMA 1988;259:2974-2974.
 

Poliomyelitis Prevention: Enhanced-Potency Inactivated Poliomyelitis Vaccine--Supplementary Statement
Arch Pediatr Adolesc Med 1988;142:139-140.
ABSTRACT  

Poliomyelitis Prevention: Enhanced-Potency Inactivated Poliomyelitis Vaccine--Supplementary Statement
JAMA 1988;259:345-346.